NEW YORK (GenomeWeb) – In an update to its 2018 breast cancer guidelines, the National Comprehensive Cancer Network (NCCN) has made changes in how it endorses the use of, or how it describes, various genetic tests. One major change involved the categorization of Genomic Health's Oncotype DX Breast Recurrence Score as a "preferred" test for chemotherapy treatment decision-making in patients with node-negative early-stage breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.